Uniting The Anti-RAS Drug Development Field- From Early Discovery to Clinical Development
Via the latest data driven case studies from academic and industry pioneers, the 2nd RAS Targeted Drug Development Summit will shine a spotlight on optimizing the selectivity and tolerability of your anti-RAS therapies, exploring novel combination strategies and overcome translational pharmacology challenges to set the stage for the 2nd generation of mutation-targeted RAS modulating therapies yet to come.
Why You Should Attend?
University of North Carolina deep dive into how the MAKP cascade can drive KRAS-dependent tumor growth and discuss the importance of the MYC oncoprotein as a key target
Verastem Oncology will explore the mechanisms of inhibitors to target KRAS mutant cancers and the method of inhibitory synergy to enhance translation and clinical development
Revolution Medicines examine approaches beyond G12C inhibition, exploring essential opportunities and platforms to optimize predictability and translation of anti-RAS combination strategies
Francis Crick Institute analyze the response of KRAS inhibitors on the tumor microenvironment and how they have examination of cellular phonotypes suggest the optimal progression for combination strategies
Kura Oncology explore their successes in reversing the undruggable nature of RAS proteins and seizing the enormous therapeutic potential in anti-RAS strategies
Following the success of RAS-Targeted Drug Discovery Summit in 2019, we will re-unite the RAS community in Boston this coming September with the most comprehensive and definitive conference specifically dedicated to this community.
Join 250+ of the leading minds from large pharma, biotech and academia across the globe who are striving to capitalise on the therapeutic opportunity of targeting RAS through advancing novel mechanisms of action, improving drug-like properties and accelerating the translation of potent and mutation-targeted 2nd generation RAS targeted therapeutic strategies into human clinical trials.